US expedited review conditions change
This article was originally published in Clinica
Executive Summary
The US FDA has issued guidance on the expedited review of premarket submissions for devices. Products are considered for expedited review if they are intended to treat or diagnose a life-threatening or debilitating condition or disease, or if they address an unmet medical need.